I've said this on the podcast before and I'll likely say it many more times:@StemoniX in easily one of the most underhyped unicorns in the making here in Minnesota.

What CEO Ping Yeh has built is incredible.

— casey allen (@casey__allen) February 28, 2019

"Instead of relying on animal models and limited human testing to predict drug interactions, @StemoniX hopes its platforms will deliver cost and time savings to the biopharma industry by enhancing the safety of human clinical trials." https://t.co/E9rEWexEm8

— Emily Trunnell PhD (@ERoseEngland) February 28, 2019